VisiJet dba Advanced Refractive Technologies Secures Distribution in Asia for EpiLift System; New Device for Laser Surgery Becomes Available in Japan, Thailand, Indonesia, Singapore, Malaysia, and Brunei.

IRVINE, Calif. -- VisiJet, Inc. (OTC BB: VJET), dba Advanced Refractive Technologies (ART), a developer and marketer of innovative technologies for the ophthalmic surgical market, has signed agreements with three different distributors to market and sell the EpiLift System in Japan, Thailand, Indonesia, Singapore, Malaysia and Brunei.

The EpiLift System, already approved for sale in Europe and in the United States, recently received approval from the Health Minister of Japan. The system is the cornerstone of Epi-LASIK, a new method of the popular LASIK corrective vision surgery. Unlike LASIK, Epi-LASIK allows the eye to heal completely post-operation, minimizing the risk of complications such as dry eye or vision impairment.

To access the Japanese market, VisiJet has entered into an agreement with Tokyo based distributor, Japan Focus. Japan Focus has been in business since 1978, and is a member of the Japan Federation of Medical Devices Association and the Japanese Society of Medical Instrumentations.

VisiJet has retained Supreme Products Co. LTD, prominent distributors of ophthalmic devices in Thailand to market and sell the EpiLift System there. The company has also signed Ning Kwong Optical Company LTD, to distribute the product to Singapore, Malaysia, Indonesia and Brunei.

"East Asia and Southeast Asia are important growth markets for a safe corrective vision surgical device," said Randy Bailey, CEO. "Our recent approval from the Health Ministry of Japan and our new distributorships give us solid footing as we ramp up our sales program in this region."

About the EpiLift System

When the EpiLift System is used, the epithelium - the top layer of the eye - is cleanly separated, at a natural division point in the eye, from the Bowman's layer membrane in an intact sheet of viable tissue. The tissue is then lifted away from the cornea so that a laser can be applied to reshape it. This entire process, Epi-LASIK, produces virtually instant visual results similar to LASIK but with the stable long-term visual outcomes of PRK.

LASIK surgery, currently a standard corrective vision surgical process, requires making a flap in the top layer of the eye before the laser is applied. This flap, once created, never fully heals, which can lead to complications and possible vision impairment in the future. Because it does not involve cutting the cornea or creating a permanent flap, the EpiLift System allows the eye to regrow the connections with the epithelium, resulting in a safer procedure with a significantly lower risk of complications.

About VisiJet

VisiJet, Inc. is a medical device company based in Irvine, California focused on the development and marketing of innovative ophthalmic applications. The company recently received FDA approval for its EpiLift system, a next-generation, ophthalmic surgical device designed for separating corneal tissue. The EpiLift system is the cornerstone of a new improvement in Lasik surgery called Epi-LASIK. The EpiLift systems improve upon existing technologies with unique separating methods that can eliminate many postoperative problems. The EpiLift system is manufactured in Germany by Gebauer Medizintechnik GmbH.

In addition to the EpiLift system, VisiJet is developing HydroKeratome(R) and Pulsatome(R), which utilize the company's proprietary and patented waterjet technology. These products result in faster, safer and more efficacious procedures in two of the largest surgical markets in the world: refractive and cataract surgeries. HydroKeratome(R) uses the waterjet technology, employing a high-pressure micro beam of water with the diameter of a human hair to cut the corneal flap as required in LASIK surgery. The Pulsatome(R) cataract emulsifier, currently under development, is a device that uses pulsed waterjet technology to remove cataracts - the most frequently performed surgical procedure in the world.

This release contains forward-looking statements that reflect the company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly, annual and other regular filings